Skip to main content

Advertisement

SpringerLink
Log in

Tumor-height regression rate after brachytherapy between choroidal melanoma gene expression profile classes: effect of controlling for tumor height

  • Oncology
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the relationship between choroidal melanoma regression rate and its gene expression profile class after iodine-125 brachytherapy at 3 and 6 months, controlling for baseline tumor height.

Methods

Patients from October 2012 to January 2015 at a single Ophthalmic Oncology Center who had undergone iodine-125 brachytherapy for the treatment of choroidal melanoma and who had a gene expression profile test result obtained from intraoperative fine-needle aspiration biopsy at the time of plaque surgery were retrospectively reviewed. Baseline patient and tumor characteristics were obtained, including tumor height and gene expression profile test result. Tumor height at 3 and 6 months following treatment was obtained. Regression rate was analyzed with two-way analysis of variance to class type and baseline pre-operative tumor height. Class 2 patients were matched to class 1 patients by tumor height and resulting distributions of paired regression rate differences were compared.

Results

A total of 114 patients were studied. When preoperative tumor height was controlled for in the comparative analysis, neither group of patients at 3 or 6 months had a significant dependency between gene expression profile class and tumor regression rate. Additionally, class 1 and class 2 patients matched for pre-operative tumor height did not express different regression rates.

Conclusions

Our study adds to a growing body of evidence that tumor regression rate does not necessarily depend on gene expression profile class type in choroidal melanoma after brachytherapy at 3 and 6 months when controlling for baseline tumor height.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Singh AD, Turell ME, Topham AK (2011) Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology 118:1881–1885. doi:10.1016/j.ophtha.2011.01.040

    Article  PubMed  Google Scholar 

  2. Augsburger JJ, Gamel JW, Shields JA et al (1987) Post-irradiation regression of choroidal melanomas as a risk factor for death from metastatic disease. Ophthalmology 94:1173–1177. doi:10.1016/S0161-6420(87)33310-X

    Article  CAS  PubMed  Google Scholar 

  3. Glynn RJ, Seddon JM, Gragoudas ES et al (1989) Evaluation of tumor regression and other prognostic factors for early and late metastasis after proton irradiation of UVeal melanoma. Ophthalmology 96:1566–1573. doi:10.1016/S0161-6420(89)32685-6

    Article  CAS  PubMed  Google Scholar 

  4. Kaiserman I, Anteby I, Chowers I et al (2004) Post-brachytherapy initial tumour regression rate correlates with metastatic spread in posterior uveal melanoma. Br J Ophthalmol 88:892–895. doi:10.1136/bjo.2003.036285

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Guthoff R, Haase J, von Domarus D et al (1990) The regression behavior of choroid melanoma following radiotherapy—a new prognostic parameter? Klin Monbl Augenheilkd 196:6–10. doi:10.1055/s-2008-1046119

    Article  CAS  PubMed  Google Scholar 

  6. Authors N (2006) The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma. Arch Ophthalmol 124:1684. doi:10.1001/archopht.124.12.1684

    Article  Google Scholar 

  7. Prescher G, Bornfeld N, Hirche H et al (1996) Prognostic implications of monosomy 3 in uveal melanoma. Lancet 347:1222–1225

    Article  CAS  PubMed  Google Scholar 

  8. Damato B, Duke C, Coupland SE et al (2007) Cytogenetics of uveal melanoma: a 7-year clinical experience. Ophthalmology 114:1925–1931. doi:10.1016/j.ophtha.2007.06.012

    Article  PubMed  Google Scholar 

  9. Van Essen TH, van Pelt SI, Versluis M et al (2014) Prognostic parameters in uveal melanoma and their association with BAP1 expression. Br J Ophthalmol 98:1738–1743. doi:10.1136/bjophthalmol-2014-305047

    Article  PubMed  Google Scholar 

  10. Van den Bosch T, van Beek JGM, Vaarwater J et al (2012) Higher percentage of FISH-determined monosomy 3 and 8q amplification in uveal melanoma cells relate to poor patient prognosis. Invest Ophthalmol Vis Sci 53:2668–2674. doi:10.1167/iovs.11-8697

    Article  PubMed  Google Scholar 

  11. Onken MD, Worley LA, Char DH et al (2012) Collaborative ocular oncology group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology 119:1596–1603. doi:10.1016/j.ophtha.2012.02.017

    Article  PubMed  PubMed Central  Google Scholar 

  12. Harbour JW, Chen R (2013) The decisiondx-UM gene expression profile test provides risk stratification and individualized patient care in uveal melanoma. PLoS Curr 12597007:1–10. doi:10.1371/currents.eogt.af8ba80fc776c8f1ce8f5dc485d4a618

    Google Scholar 

  13. Shields CL, Furuta M, Berman EL et al (2009) Choroidal nevus transformation into melanoma: analysis of 2514 consecutive cases. Arch Ophthalmol 127:981–987. doi:10.1001/archophthalmol.2009.151

    Article  PubMed  Google Scholar 

  14. Marathe OS, Wu J, Lee SP et al (2011) Ocular response of choroidal melanoma with monosomy 3 versus disomy 3 after iodine-125 brachytherapy. Int J Radiat Oncol Biol Phys 81:1046–1048. doi:10.1016/j.ijrobp.2010.07.016

    Article  PubMed  Google Scholar 

  15. Chiam PJT, Coupland SE, Kalirai H et al (2014) Does choroidal melanoma regression correlate with chromosome 3 loss after ruthenium brachytherapy? Br J Ophthalmol 98:967–971. doi:10.1136/bjophthalmol-2013-304472

    Article  PubMed  Google Scholar 

  16. Rao RC, Khan M, Badiyan SN, Harbour JW (2015) Gene expression profiling and regression rate of irradiated uveal melanomas. Ophthalmic Surg Lasers Imaging Retina 46:333–337. doi:10.3928/23258160-20150323-06

    Article  PubMed  PubMed Central  Google Scholar 

  17. Chen RWS, Harbour JW (2014) Rapid regression of a subset of class 1 uveal melanomas after Iodine-125 plaque radiotherapy suggests an inflammatory mechanism. Graefes Arch Clin Exp Ophthalmol 252:2021–2022. doi:10.1007/s00417-014-2793-1

    Article  PubMed  PubMed Central  Google Scholar 

  18. Corrêa ZM, Augsburger JJ (2014) Relationship between rate of posterior uveal melanoma flattening following plaque radiotherapy and gene expression profile class of tumor cells. Invest Ophthalmol Vis Sci 55:556–559. doi:10.1167/iovs.13-13381

    Article  PubMed  Google Scholar 

  19. Demirci H, Saponara F, Khan A et al (2015) Regression rate of posterior uveal melanomas following iodine-125 plaque radiotherapy. Middle East Afr J Ophthalmol 22:103. doi:10.4103/0974-9233.148358

    Article  PubMed  PubMed Central  Google Scholar 

  20. Chappell MC, Char DH, Cole TB et al (2012) Uveal melanoma: molecular pattern, clinical features, and radiation response. Am J Ophthalmol 154:227–232. doi:10.1016/j.ajo.2012.02.022

    Article  PubMed  Google Scholar 

  21. Shields CL, Ganguly A, Materin MA et al (2007) Chromosome 3 analysis of uveal melanoma using fine-needle aspiration biopsy at the time of plaque radiotherapy in 140 consecutive cases. Trans Am Ophthalmol Soc 105:43–52, discussion 52–3

    PubMed  PubMed Central  Google Scholar 

  22. Onken MD, Worley LA, Dávila RM et al (2006) Prognostic testing in uveal melanoma by transcriptomic profiling of fine-needle biopsy specimens. J Mol Diagn 8:567–573. doi:10.2353/jmoldx.2006.060077

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Faulkner-Jones BE, Foster WJ, Harbour JW et al (2005) Fine needle aspiration biopsy with adjunct immunohistochemistry in intraocular tumor management. Acta Cytol 49:297–308

    Article  PubMed  Google Scholar 

  24. McCannel TA, Chang MY, Burgess BL (2012) Multi-year follow-up of fine-needle aspiration biopsy in choroidal melanoma. Ophthalmology 119:606–610. doi:10.1016/j.ophtha.2011.08.046

    Article  PubMed  Google Scholar 

  25. Simpson ER, Gallie B, Laperrierre N et al (2014) The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy 13:1–14. doi:10.1016/j.brachy.2013.11.008

    Article  Google Scholar 

  26. Cruess AF, Augsburger JJ, Shields JA et al (1984) Regression of posterior uveal melanomas following cobalt-60 plaque radiotherapy. Ophthalmology 91:1716–1719

    Article  CAS  PubMed  Google Scholar 

  27. Rashid M, Heikkonen J, Kivelä T (2015) Tumor regression after brachytherapy for choroidal melanoma: reduction of thickness and cross-sectional area by shape and regression pattern. Invest Ophthalmol Vis Sci. doi:10.1167/iovs.14-16322

    PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

We would like to thank Dr. Jason Wang, biostatistician in the Department of Radiation Oncology at Ronald Reagan UCLA Medical Center, for his assistance reviewing the article.

Author information

Authors and Affiliations

  1. Stein Eye and Doheny Eye Institutes, Department of Ophthalmology, University of California, Los Angeles, 100 Stein Plaza, Los Angeles, CA, 90095, USA

    Kishan Gupta, Colin A. McCannel, Robert D. Almanzor & Tara A. McCannel

  2. David Geffen School of Medicine, University of California, Los Angeles, 10833 Le Conte Avenue, 12-109, Los Angeles, CA, 90095, USA

    Kishan Gupta

  3. Department of Radiation Oncology, University of California, Los Angeles, 200 Medical Plaza, Los Angeles, CA, 90095, USA

    Mitchell Kamrava & James Lamb

  4. Stein Eye Institute, University of California, Los Angeles, 200 Stein Plaza, Los Angeles, CA, 90095, USA

    Tara A. McCannel

Authors
  1. Kishan Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Colin A. McCannel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mitchell Kamrava
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. James Lamb
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robert D. Almanzor
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tara A. McCannel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tara A. McCannel.

Ethics declarations

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Funding

This research was generously supported by the George E. and Ruth Moss Trust and an unrestricted grant from Research to Prevent Blindness. The sponsor had no role in the design or conduct of this research.

Conflict of interest

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

Informed consent

Informed consent was obtained from all individual participants included in the study. Formal consent is not required, however, for this retrospective analysis.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gupta, K., McCannel, C.A., Kamrava, M. et al. Tumor-height regression rate after brachytherapy between choroidal melanoma gene expression profile classes: effect of controlling for tumor height. Graefes Arch Clin Exp Ophthalmol 254, 1371–1378 (2016). https://doi.org/10.1007/s00417-016-3305-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-016-3305-2

Keywords

Search

Navigation